FIELD: medicine; neurology.
SUBSTANCE: present invention relates to treating sleep disorders. That is ensured by administering a pharmaceutical composition containing SON-117 or its metabolite, or a combination thereof, in low doses.
EFFECT: it provides effective correction of sleep disorders, in particular increase of slow sleep period, due to antagonistic activity of said compounds with respect to 5-HT1A receptor, as well as their ability to inhibit re-uptake of 5-HT.
15 cl, 37 dwg, 26 tbl
Authors
Dates
2020-06-29—Published
2014-01-24—Filed